ALRN Stock Summary and Trading Ideas (Aileron Therapeutics | NASDAQ:ALRN)

Aileron Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on developing a novel class of therapeutics for the treatment of cancer and other diseases. The company's lead product candidate, ALRN-6924 is a novel chemoprotective medicine to treat and protect healthy cells in patients with cancer that harbors p53 mutations to reduce or eliminate chemotherapy-induced side effects. The company currently has two product candidates in clinical development, LTI-03 and LTI-01, and multiple candidates in preclinical development focused on fibrosis indications.

Aileron Therapeutics trades on the NASDAQ stock market under the symbol ALRN.

As of April 23, 2024, ALRN stock price was flat at $4.75 with 67,286 million shares trading.

ALRN has a beta of 2.86, meaning it tends to be more sensitive to market movements. ALRN has a correlation of 0.12 to the broad based SPY ETF.

ALRN has a market cap of $80.62 million. This is considered a Micro Cap stock.

In the last 3 years, ALRN stock traded as high as $28.00 and as low as $1.01.

The top ETF exchange traded funds that ALRN belongs to (by Net Assets): VXF, ONEQ.

ALRN has outperformed the market in the last year with a return of +216.7%, while the SPY ETF gained +24.3%. In the last 3 month period, ALRN beat the market returning +16.7%, while SPY returned +4.9%. However, in the most recent 2 weeks ALRN has underperformed the stock market by returning -23.4%, while SPY returned -2.5%.

ALRN support price is $4.28 and resistance is $5.22 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ALRN stock will trade within this expected range on the day.